Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

BACKGROUND: Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6. In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved progression-free survival (PFS) compared with letrozole alone as first-line treatment of...

Full description

Saved in:
Bibliographic Details
Published in:Breast Cancer Res
Main Authors: Finn, Richard S., Crown, John P., Ettl, Johannes, Schmidt, Marcus, Bondarenko, Igor M., Lang, Istvan, Pinter, Tamas, Boer, Katalin, Patel, Ravindranath, Randolph, Sophia, Kim, Sindy T., Huang, Xin, Schnell, Patrick, Nadanaciva, Sashi, Bartlett, Cynthia Huang, Slamon, Dennis J.
Format: Artigo
Language:Inglês
Published: BioMed Central 2016
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924326/
https://ncbi.nlm.nih.gov/pubmed/27349747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-016-0721-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items